How should elevated SGPT (ALT) be evaluated and managed in a pregnant woman?

Elevated SGPT (ALT) in Pregnancy: Evaluation and Management

Any elevation in ALT during pregnancy is pathologic and requires immediate systematic investigation, as normal pregnancy does not alter aminotransferase levels. 1, 2

Initial Diagnostic Workup

Obtain the following tests immediately when elevated ALT is detected:

• Complete liver panel: AST, ALT, alkaline phosphatase, GGT, total and direct bilirubin, albumin 2
• Pregnancy-specific markers: Non-fasting serum bile acids, complete blood count with platelet count, coagulation studies (PT/INR, fibrinogen), uric acid, creatinine, lactate 2
• Blood pressure and urine protein to screen for preeclampsia 2
• Viral hepatitis panel: HAV IgM, HBsAg, HBc IgM, HCV antibody, HEV IgM 2
• Comprehensive medication history including over-the-counter and herbal products to identify drug-induced liver injury 1, 2
• Alcohol use screening 1, 2

Trimester-Specific Differential Diagnosis

First Trimester (0-12 weeks)

• Hyperemesis gravidarum causes mild ALT elevation (typically <300 IU/L) in 40-50% of severe cases; this is self-limiting with supportive care 1, 2, 3
• Screen for coincidental viral hepatitis, autoimmune hepatitis, Wilson disease, or drug-induced liver injury 2

Second and Third Trimester (13-40 weeks)

The differential diagnosis narrows based on the pattern and severity of ALT elevation:

Intrahepatic Cholestasis of Pregnancy (ICP)

• Diagnosis: Serum bile acids >10 μmol/L plus generalized pruritus (especially palms/soles), typically after 30 weeks 1, 2, 3
• ALT may be elevated 2-30 times the upper limit of normal 2, 3
• Management:
  • Measure bile acids weekly from 32 weeks' gestation 1, 2
  • Initiate ursodeoxycholic acid (UDCA) 10-15 mg/kg/day in divided doses when bile acids >40 μmol/L to reduce pruritus and spontaneous preterm birth risk 1, 2
  • Delivery timing based on bile acid levels:

    • 100 μmol/L → deliver at 35-36 weeks due to markedly increased stillbirth risk 1, 2

    • 40-100 μmol/L → deliver at 36-39 weeks 1, 2
    • <40 μmol/L → aim for term delivery at 39 weeks 1, 2
  • For refractory pruritus, consider rifampicin, cholestyramine, guar gum, or activated charcoal 2

HELLP Syndrome

• Diagnosis: Hemolysis (elevated LDH, schistocytes), elevated liver enzymes (AST/ALT 2-10× ULN), low platelets (<100×10⁹/L), typically after 20 weeks 1, 2, 3
• Hypertension and proteinuria may be absent in up to 15% of cases 2
• Management:
  • Transfuse platelets when count <100×10⁹/L 1, 2
  • Control severe hypertension (SBP >160 or DBP >110 mmHg) urgently with IV/oral labetalol, nifedipine, or methyldopa 1, 2
  • Administer magnesium sulfate to prevent eclamptic seizures 1, 2
  • Deliver promptly once maternal coagulopathy and severe hypertension are corrected; delayed delivery increases maternal mortality 1, 2
  • Obtain abdominal ultrasound if severe epigastric or right upper quadrant pain develops to assess for hepatic hematoma or rupture 2

Acute Fatty Liver of Pregnancy (AFLP)

• Diagnosis: ALT typically 300-500 IU/L, bilirubin <5 mg/dL, marked coagulopathy (prolonged PT/INR, low fibrinogen), hypoglycemia, elevated lactate 2, 4
• Can occur as early as the second trimester, though typically third trimester 4
• Management:
  • Admit to ICU if encephalopathy, lactate >2.8 mmol/L, MELD >30, or Swansea score >7 2
  • Aggressively correct coagulopathy and metabolic derangements (hypoglycemia, hyperammonemia) 2
  • Expedite delivery once maternal stabilization achieved 1, 2, 4
  • Consider plasma exchange post-delivery for severe hepatic impairment 2
  • Consider N-acetylcysteine for ICU-level disease 2
  • Early referral to transplant center for severe hepatic failure or lack of post-delivery improvement 2

Imaging Strategy

• First-line: Abdominal ultrasound without Doppler—safe at any gestational age, evaluates biliary tree, liver parenchyma, and vasculature 1, 2
• Second-line: MRI or MRCP without gadolinium—preferred over CT, safe in all trimesters 1, 2
• Avoid gadolinium throughout pregnancy as it crosses the placenta 2
• ERCP can be performed when clinically necessary (fetal radiation <0.5 mGy), ideally in second/third trimester 1, 2

Critical Pitfalls to Avoid

• Do not assume elevated ALT is normal in pregnancy—it always requires investigation 1, 2
• Do not delay delivery in preeclampsia, HELLP, or AFLP after maternal stabilization; postponement increases maternal mortality 2
• Do not diagnose ICP based on elevated ALT alone—bile acids must be >10 μmol/L with pruritus 2, 3
• Do not stop immunosuppressive medications or disease-modifying treatments in women with pre-existing liver disease, as clinical deterioration poses greater risk 1
• Recognize that AFLP can present in the second trimester, not just the third 4
• Elevated ALT in early pregnancy (first trimester) is associated with increased risk of gestational diabetes and preeclampsia later in pregnancy 5, 6

Multidisciplinary Management

All pregnant women with elevated ALT and confirmed liver disease should be managed by a multidisciplinary team including hepatology/gastroenterology, maternal-fetal medicine, and obstetrics specialists 2

Post-partum Follow-up

• Monitor liver function tests until normalization, typically within 3 months post-delivery 1, 2, 3
• If abnormalities persist beyond 3-6 weeks, investigate for underlying chronic liver disease 1, 2
• Women with ICP have 45-90% recurrence risk in subsequent pregnancies 2, 3
• Up to 70% of women with pre-existing cholestatic liver disease experience post-natal worsening of liver tests, requiring close postpartum monitoring 1, 2